Thymine-beta-D-arabinofuranoside structure
|
Common Name | Thymine-beta-D-arabinofuranoside | ||
|---|---|---|---|---|
| CAS Number | 605-23-2 | Molecular Weight | 258.23 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C10H14N2O6 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Thymine-beta-D-arabinofuranosideThymine 1-β-D-arabinofuranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. |
| Name | 1-.β.-D-Arabinofuranosylthymine |
|---|---|
| Synonym | More Synonyms |
| Description | Thymine 1-β-D-arabinofuranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C10H14N2O6 |
| Molecular Weight | 258.23 |
| Exact Mass | 258.085175 |
| PSA | 124.78000 |
| LogP | -1.02 |
| Index of Refraction | 1.619 |
| InChIKey | DWRXFEITVBNRMK-JAGXHNFQSA-N |
| SMILES | Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | XP2100200 |
| Precursor 9 | |
|---|---|
| DownStream 1 | |
|
Image guided drug release from pH-sensitive Ion channel-functionalized stealth liposomes into an in vivo glioblastoma model.
Nanomedicine: Nanotechnology, Biology, and Medicine 11 , 1345-54, (2015) Liposomal drug delivery vehicles are promising nanomedicine tools for bringing cytotoxic drugs to cancerous tissues selectively. However, the triggered cargo release from liposomes in response to a ta... |
|
|
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Sci. Transl. Med. 7 , 315ra188, (2015) Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particular... |
|
|
iTRAQ-Based Quantitative Proteomic Analysis of Tear Fluid in a Rat Penetrating Keratoplasty Model With Acute Corneal Allograft Rejection.
Invest. Ophthalmol. Vis. Sci. 56 , 4117-24, (2015) This study aimed to develop a greater understanding of the mechanisms underlying acute corneal allograft rejection by identifying differentially expressed tear proteins at defined stages and discoveri... |
| Thymine arabinofuranoside |
| Thymine, 1-β-D-arabinofuranosyl- |
| 1-(β-D-Arabinofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione |
| spongothymidine |
| thymine arabinoside |
| ARABINOFURANOSYL-5-METHYLURACIL |
| EINECS 210-083-7 |
| MFCD00065474 |
| 1-(β-D-arabinofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione |
| 1-[3,4-Dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidindion |
| 5-Methyl-1-pentofuranosyl-2,4(1H,3H)-pyrimidinedione |
| ARA-T |
| 5-Methyl-1-pentofuranosylpyrimidine-2,4(1H,3H)-dione |
| 2,4(1H,3H)-Pyrimidinedione, 1-β-D-arabinofuranosyl-5-methyl- |
| 1-[3,4-Dihydroxy-5-(hydroxyméthyl)tétrahydro-2-furanyl]-5-méthyl-2,4(1H,3H)-pyrimidinedione |
| 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-pentofuranosyl- |
| 1-B-D-Arabinofuranosylthymine |
| spongothymidin |
| Arabinofuranosylthymine |
| 1-[3,4-Dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione |
| Thymine 1-beta-D-arabinofuranoside |
| 1-β-D-Arabinofuranosylthymine |
| arabinosylthymine |